



REFERENCES

www.interpflow.com
info@interpflow.com

References

- 1- Van Dongen JJ et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal , reactive and malignant leukocytes. *Leukemia* 2012;26:1908-1975.
- 2- Foon KA, Todd RF, 3rd. Immunologic classification of leukemia and lymphoma. *Blood* 1986 Jul ; 68(1): 1-31.
- 3- van Dongen JJ, Adriaansen HJ, Hooijkaas H. Immunophenotyping of leukaemias and non-Hodgkin's lymphomas. Immunological markers and their CD codes. *Neth J Med* 1988 Dec; 33(5 -6): 298-314.
- 4- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer: Lyon, 2008, 439 p.pp
- 5- Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. *Blood* 2008 Apr 15; 111(8): 3941-3967.
- 6- Borowitz MJ, Chan JKC. T lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer: Lyon, 2008, p p 176-178.
- 7- Stetler-Stevenson M, Davis B, Wood B, Braylan R. 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia. *Cytometry B Clin in Cytom* 2007; 72 Suppl 1: S3.
- 8- van den Ancker W, Terwijn M, Westers TM, Merle PA, van Beckhoven E, Drager AM, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. *Leukemia* 2010 Jul; 24(7): 1392-1396.
- 9- Mejstrikova E, Volejnikova J, Fronkova E, Zdrahalova K, Kalina T, Sterba J, et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. *Haematologica* 2010 Jun; 95(6): 928-935.
- 10- Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood* 2011 Mar 17; 117(11): 3163-3171.
- 11- Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. *Lancet Oncol* 2001 Jul; 2(7): 409-417.
- 12- Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. *Leuk Res* 2008 Jan; 32(1): 5-17.
- 13- Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. *Blood* 2001 Aug 15; 98(4): 979-987.
- 14- van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppelaar GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. *Blood* 2008 Feb 1; 111(3): 1067-1077.
- 15- Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and Bcell lineagecommitted CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. *Leukemia* 2008 Jun; 22(6): 1175-1183.

- 16- Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. *Leukemia* 2005 May; 19(5): 776-783.
- 17- Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Peripheral blood MDS score : a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. *Cytometry B Clin Cytom* 2005 Mar; 64(1): 9-17
- 18- Aul C, Giagounidis A, Heinsch M, Germing U, Ganser A. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. *Rev Clin Exp Hematol* 2004 Dec; 8(2): E1.
- 19- Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. *Leukemia* 2006 Apr; 20(4): 549-555.
- 20- Font P, Subira D, Mtnez-Chamorro C, Castanon S, Arranz E, Ramiro S, et al. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. *Leuk Res* 2006 Aug; 30(8): 957-963.
- 21- Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L, et al. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. *Leuk Res* 2008 Nov; 32(11): 1715-1723.
- 22- Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. *Blood* 2008 Oct 1; 112(7): 2681-2686.
- 23- van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. *Haematologica* 2009 Aug; 94(8): 1124-1134.
- 24- Van de Loosdrecht AA, Ireland R, Kern W, Alhan C, Balleissen JS, Bene MC, et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes. Position paper of the European LeukemiaNet working group on flow cytometry in myelodysplastic syndromes. *Leukemia*, in press 2012.
- 25- Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. *Best Pract Res Clin Haematol* 2007 Dec; 20(4): 637-664
- 26- Rawstron AC, Orfao A, Beksac M, Bezdicova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica* 2008 Mar; 93(3): 431-438
- 27- Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. *Cytometry B Clin Cytom* 2010 Jul; 78(4): 239-252.